Before The Next Spoonful: New Cough Syrup Rules For Under-4s

India has tightened restrictions on certain cough and cold medicines for children below four years, adding to a series of regulatory measures introduced over the past year. The latest move targets fixed-dose combination medicines containing chlorpheniramine maleate and phenylephrine hydrochloride. The Centre has restricted the manufacture, sale and distribution of these formulations for use in children below four and directed that products carry a prominent warning stating that they should not be used in this age group.

The latest order follows recommendations from an expert committee and the Drugs Technical Advisory Board, which flagged potential risks associated with the combination in young children and noted that safer alternatives are available. Chlorpheniramine is an antihistamine, while phenylephrine is a decongestant commonly used for symptoms such as a runny or blocked nose and sneezing. The government had already imposed restrictions involving the same ingredients in April 2025, but the August 2026 notification extends the restriction to all formulations containing the combination.

The decision comes amid increased scrutiny of cough and cold medicines in India following a series of safety concerns. In 2025, children in Madhya Pradesh died after consuming contaminated cough syrup, prompting investigations and wider concern over medicine quality and manufacturing standards. The World Health Organization later issued a medical product alert over specific contaminated oral liquid medicines after diethylene glycol was detected. The episode also renewed attention on the risks associated with certain cough and cold formulations for young children.

Also Read: Dr Pushkar Chawla Reveals How Desk Workers Can Prevent Back And Spine Problems

Several other regulatory steps have followed. In October 2025, the Union Health Ministry advised against prescribing or dispensing cough and cold medicines to children below two years and urged caution in their use among children up to five. In January 2026, Tamil Nadu banned a cough syrup after laboratory testing detected ethylene glycol. In June, the Centre removed syrups from an exemption under Schedule K of the Drugs Rules, 1945, making prescription-based dispensing applicable to syrup medicines that had previously benefited from the exemption.

The latest order does not mean that every cough syrup has been banned for children below four. It specifically applies to fixed-dose combinations containing chlorpheniramine maleate and phenylephrine hydrochloride. Health guidance has also emphasised that children do not necessarily require cough medicine for every cough, particularly when symptoms are linked to common viral respiratory infections. Parents should avoid giving medicines based on another child's prescription, an earlier prescription or informal advice, and should consider the child's age, weight, symptoms and the ingredients in the formulation.

For parents, the key precaution is to check the active ingredients and follow appropriate medical advice before giving cough or cold medicines to young children. Medicines containing the chlorpheniramine-phenylephrine combination should not be used in children below four years under the latest restriction. If a child's cough is accompanied by breathing difficulty, persistent high fever, poor feeding, unusual drowsiness, dehydration or worsening symptoms, medical evaluation is important rather than relying solely on symptom-relief medicines.

Also Read: Raksha Bandhan 2026: 4 Simple Homemade Treats For A Special Celebration